{"id":13246,"date":"2026-10-12T10:15:25","date_gmt":"2026-10-12T10:15:25","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=13246"},"modified":"2026-10-12T10:15:25","modified_gmt":"2026-10-12T10:15:25","slug":"how-does-mounjaro-work-inside-the-mounjaro-kwikpen","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/how-does-mounjaro-work-inside-the-mounjaro-kwikpen\/","title":{"rendered":"How Does Mounjaro Work? Inside the Mounjaro KwikPen"},"content":{"rendered":"\n

A client starting her second month on Mounjaro<\/mark><\/a> says something aesthetic practitioners<\/mark><\/a> now hear often. The constant thinking about food has gone quiet, she feels full after half a plate, and she wants to know whether the injection is \u201cdoing something to her brain<\/em>\u201d. The short answer is yes, along with her pancreas, stomach and fat tissue.<\/p>\n\n\n\n

Mounjaro is the brand name for tirzepatide<\/strong>. Knowing how it works makes the practical questions easier to answer: why the stomach feels different, why doses rise slowly, why results take months, and why appetite returns when treatment stops.<\/p>\n\n\n\n

Mounjaro Injection Explained: How Mounjaro KwikPen Acts on GIP and GLP-1<\/h2>\n\n\n\n

Tirzepatide, the active ingredient in Mounjaro KwikPen, is a single 39-amino-acid peptide that activates two gut hormone receptors. According to Eli Lilly\u2019s explanation of how tirzepatide differs from GLP-1 receptor agonists<\/mark><\/a>, it is built on the native GIP sequence and modified so that it also binds the GLP-1 receptor. That makes it a dual agonist. Semaglutide and liraglutide act on the GLP-1 receptor alone.<\/p>\n\n\n\n

GIP<\/strong> (glucose-dependent insulinotropic polypeptide) and GLP-1<\/strong> (glucagon-like peptide-1) are incretins. These hormones are released from the gut after eating, and they tell the body that food has arrived. Natural GLP-1 is broken down within minutes. The Mounjaro injection delivers a version engineered to resist that breakdown, so it stays active for days.<\/p>\n\n\n\n

The molecule is also imbalanced. Tirzepatide binds the GIP receptor with roughly the same strength as natural GIP, but binds the GLP-1 receptor more weakly than natural GLP-1. At the GLP-1 receptor it also favours signalling pathways that cause less receptor internalisation. Researchers think this may help sustain the response over time, though the clinical importance of this bias is still being studied.<\/p>\n\n\n\n

The GLP-1 Receptor: Insulin, Glucagon and the Stomach<\/strong><\/h3>\n\n\n\n

GLP-1 receptor activation has three well-established effects:<\/p>\n\n\n\n

    \n
  1. Insulin release on demand.<\/strong> It increases insulin release only when blood glucose is raised. This glucose dependence is why tirzepatide alone rarely causes hypoglycaemia.<\/li>\n\n\n\n
  2. Less glucagon.<\/strong> It suppresses glucagon, the hormone that tells the liver to release glucose.<\/li>\n\n\n\n
  3. Slower gastric emptying.<\/strong> It slows the rate at which the stomach empties into the small intestine.<\/li>\n<\/ol>\n\n\n\n

    The third effect explains much of what patients feel. Food stays in the stomach longer, so fullness arrives sooner and lasts longer. The same effect causes nausea, reflux and burping, especially after fatty meals or large portions. The slowing is strongest after the first doses and after each dose increase, then partly fades as the body adapts. That is why gastrointestinal effects cluster around dose increases.<\/p>\n\n\n\n

    Slower gastric emptying also changes how oral medicines are absorbed. This is the reason for the MHRA contraception advice reported by Pulse<\/mark><\/a>: women using oral contraception are advised to add a barrier method, because tirzepatide may make the pill less effective. Prescribers also monitor patients on oral medicines with a narrow therapeutic range, such as warfarin.<\/p>\n\n\n\n

    The GIP Receptor: The Part Still Being Debated<\/strong><\/h3>\n\n\n\n

    GIP is the more surprising half of the molecule. For years, researchers expected that activating GIP receptors would not help weight loss. Some animal studies even suggested that blocking them causes weight loss.<\/p>\n\n\n\n

    Current evidence points to several possible roles for GIP receptor activation:<\/p>\n\n\n\n